English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The incidence and prevalence of critical limb ischaemia (CLI) is progressively increasing, mainly because of the widespread incidence of diabetes mellitus and longer life expectancy in developed countries.1 Beyond lifestyle changes and medical therapy, arterial revascularisation is a mainstay in the management of patients with CLI due to below-the-knee (BTK) disease in order to improve functional class and prevent complications possibly leading to amputation and limb loss.2 Until recently vascular surgery by means of distal bypasses was considered the only feasible revascularisation option,1,2 but the introduction of dedicated techniques and devices has shown that percutaneous arterial revascularisation by means of percutaneous transluminal angioplasty (PTA) is feasible and safe in these patients, with satisfactory clinical results.3,4 Furthermore, the landmark Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial indicates that a percutaneous revascularisation strategy is probably equivalent to bypass surgery in patients with CLI.5 However, there remains room for improvement, as PTA may carry risks of suboptimal result, abrupt vessel closure or late restenosis or re-occlusion.

Initial Clinical Experience with a Novel Dedicated Cobalt–Chromium Stent for the Treatment of Below-the-knee Arterial Disease